Search

Displaying results 1041 - 1050 of 4600 in total
  1. Drug

    PA-1050040

    go.drugbank.com/drugs/DB06039
    Experimental

    It inhibits virus replication by the same mechanism of action as BVM.

  2. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.

  3. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. … [A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene

  4. Drug

    Desloratadine

    go.drugbank.com/drugs/DB00967
    ApprovedInvestigational

    Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a l...

    Mixtures: AIRCOMB 2,5 MG/4 MG GRANÜL İÇEREN SAŞE, 30 ADET, AIRCOMB 2,5 MG/4 MG GRANÜL İÇEREN SAŞE, 90 ADET
  5. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  6. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.

  7. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    [A274073] Tiratricol is currently being investigated in US clinical trials. … by chronic tissue thyrotoxicosis and abnormal neuronal development due to the impaired thyroid hormone uptake in the brain.

  8. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.

  9. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks for adult dialysis patients with anemia of CKD but … [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis.

  10. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine]. … [L39050] Molnupiravir was also granted emergency use authorization by the FDA on December 23, 2021; however, it is not yet fully approved.[L39588]